与 «मदनफल»相关的印地语书籍
在以下的参考文献中发现
मदनफल的用法。与
मदनफल相关的书籍以及同一来源的简短摘要提供其在 印地语文献中的使用情境。
1
The American Psychiatric Publishing Textbook of ... - Page 850
Modafinil, the primary metabolite of adrafinil, lacks adrafinil's terminal amide hydroxyl group (Figure 43–1). It also lacks many of the side effects found in adrafinil, such as increased liver enzymes, anxiety, and stomach pain. Modafinil is rapidly ...
Alan F. Schatzberg, Charles B. Nemeroff,
2009
2
2009 Nurse's Drug Handbook - Page 682
of modafinil contraceptive-containing implants or devices, oral contraceptives: Possibly contraceptive failure cyclosporine: Possibly decreased blood cyclosporine level and increased risk of organ transplant rejection deacamethasone, ...
Jones & Bartlett Publishers,
2008
3
PNDR, Psychologists' Neuropsychotropic Drug Reference - Page 248
The exact mechanism of modafinil's CNS stimulant action for the symptomatic managemento narcolepsy has not yet fully been determined. However, it appears primarily to involve: 1) stim ulation of a-1 adrenergic receptors; 2) increase in the ...
Louis A. Pagliaro, Ann M. Pagliaro,
1999
4
Peripheral Vascular Disease: Basic Diagnostic and ... - Page 163
After oral administration of tadalafil, the peak serum concentration is reached in 2 hours. The half-life of the drug is 17.5 hours, leading to a much longer time period of effectiveness. The IC50 for PDE5 is higher than that of sildenafil. Tadalafil ...
5
Essential Psychopharmacology: the Prescriber's Guide - Page 315
Drug Interactions • May increase plasma levels of drugs metabolized by CYP450.2019 (e.g., diazepam, phenytoin, propranolol) • Modafinil may increase plasma levels of CYP4502D6 substrates such astricyclic antidepressants and SSRIs, ...
S. M. Stahl, Stephen M. Stahl,
2005
6
Cyclic Nucleotide Phosphodiesterases in Health and Disease
Currently, tadalafil, a PDE5 inhibitor (IC50=6.7nM), is the most effective PDE11A inhibitor with IC50 value of 73 nM for PDE11A4.” Other potent PDE5 inhibitors, i.e., sildenafil (IC50=3.7nM) and vardenafil (IC50= 0.091 nM), are less effective in ...
Joseph A. Beavo, Sharron H. Francis, Miles D. Houslay,
2006
7
The Neuroscience of Sleep - Page 191
Modafinil Modafinil is a nonamphetamine, wakefulness-promoting drug that has Food and Drug Administration (FDA) approval for the treatment of excessive sleepiness in the following disorders: narcolepsy, residual sleepiness in continuous ...
Robert Stickgold, Matthew P. Walker,
2010
8
Drug Interactions in Infectious Diseases - Page 453
Tadalafil Vardenafil PAHL: Tadalafil 20 mg QD; increase to 40 mg QD based on tolerability. If maintained on tadalafil and starting ATV (+RTV), stop tadalafil 224 h before starting ATV (+RTV), after at least 1-week later, resume at 20 mg QD.
Stephen C. Piscitelli, Keith A. Rodvold, Manjunath P. Pai,
2011
9
Narcolepsy: A Clinical Guide - Page 275
In vitro, modafinil/armodafinil binds to the dopamine transporter and inhibits dopamine reuptake [17, 23]. These binding inhibitory effects have been shown to be associated with increased extracellular dopamine levels in the striatum in rats ...
Meeta Goswami, Seithikurippu Ratnas Pandi-Perumal, Michael J. Thorpy,
2011
10
Essential Psychopharmacology: The Prescriber's Guide: ... - Page 339
Drug Interactions • May increase plasma levels of drugs metabolized by CYP450 2C19 (e.g., diazepam, phenytoin, propranolol) • Modafinil may increase plasma levels of CYP450 2D6 substrates such as tricyclic antidepressants and SSRIs, ...